| Date | Title | Description |
| 03.11.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | In the labyrinth of Alzheimer’s disease, a new light flickers. Lecanemab, a monoclonal antibody, has emerged as a promising treatment, showing potential to slow cognitive decline in early-stage patients. Recent data presented at the Clinica... |
| 01.11.2024 | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Fri, Nov 01, 2024 00:30 CET Report this content
Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: ... |
| 31.10.2024 | The Rise of Leqembi: A New Dawn in Alzheimer’s Treatment | In the world of Alzheimer’s research, a beacon of hope shines brighter than ever. Leqembi, a drug developed through a partnership between BioArctic and Eisai, is making waves. The latest reports reveal that Leqembi generated JPY 10 billion ... |
| 31.10.2024 | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
Thu, Oct 31, 2024 08:30 CET Report this content
Stockholm, Sweden October 31, 2024 – BioArctic AB’... |
| 30.10.2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
Wed, Oct 30, 2024 11:45 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 30.10.2024 | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
Wed, Oct 30, 2024 08:30 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB (publ) (Na... |
| 29.10.2024 | Massachusetts: The Beacon of Sustainable Biotech Innovation | Massachusetts is a powerhouse in biotechnology. It’s a state where innovation blooms like spring flowers. The rich soil of education, research, and collaboration nurtures groundbreaking advancements. This article explores how Massachusetts ... |
| 24.10.2024 | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
Thu, Oct 24, 2024 08:00 CET Report this content
Stockholm, October 24, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented wit... |
| 17.10.2024 | BioArctic and Eisai: Navigating the Waters of Alzheimer’s Treatment | In the world of biopharma, few stories resonate as powerfully as the quest to combat Alzheimer’s disease. BioArctic AB, a Swedish company, stands at the forefront of this battle. Their flagship product, Leqembi® (lecanemab), has emerged as ... |
| 17.10.2024 | Eisai will request reconsideration of initial decision for lecanemab in Australia | Eisai will request reconsideration of initial decision for lecanemab in Australia
Thu, Oct 17, 2024 01:30 CET Report this content
Stockholm, Sweden October 17, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced to... |
| 11.10.2024 | BioArctic presents Nomination Committee | BioArctic presents Nomination Committee
Fri, Oct 11, 2024 08:30 CET Report this content
Stockholm, Sweden, October 11, 2024 – Pursuant to the instruction regarding the appointment of the Nomination Committee BioArctic AB’s (publ) (Nasdaq St... |
| 30.09.2024 | Number of shares and votes in BioArctic AB (publ) as of September 30, 2024 | Number of shares and votes in BioArctic AB (publ) as of September 30, 2024
Mon, Sep 30, 2024 18:30 CET Report this content
Stockholm, September 30, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company durin... |
| 29.08.2024 | Interim Report for the period April – June 2024 | Interim Report for the period April – June 2024
Thu, Aug 29, 2024 08:00 CET Report this content
Lecanemab authorised in Great Britain and EU re-examination in progress
Events during the second quarter 2024 BioArctic and Eisai entered into a... |
| 27.08.2024 | Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology | Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
Tue, Aug 27, 2024 08:00 CET Report this content
Stockholm, August 27, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced toda... |
| 22.08.2024 | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain
Thu, Aug 22, 2024 11:05 CET Report this content
Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today t... |
| 22.08.2024 | Regarding rumors of an imminent approval of lecanemab in Great Britain | Regarding rumors of an imminent approval of lecanemab in Great Britain
Thu, Aug 22, 2024 08:34 CET Report this content
Stockholm, Sweden August 22, 2024 – British media are reporting on the imminent approval of lecanemab in Great Britain. B... |
| 19.08.2024 | Invitation to presentation of BioArctic’s second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
Mon, Aug 19, 2024 08:30 CET Report this content
Stockholm, Sweden, August 15, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: ... |
| 14.08.2024 | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates
Wed, Aug 14, 2024 01:00 CET Report this content
Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announ... |
| 01.08.2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024
Thu, Aug 01, 2024 12:45 CET Report this content
Stockholm, Sweden, August 1, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today ... |
| 31.07.2024 | Lecanemab: A Beacon of Hope in the Fight Against Alzheimer’s Disease | In the battle against Alzheimer’s disease, a new warrior has emerged: lecanemab, marketed as LEQEMBI. Recent findings presented at the Alzheimer’s Association International Conference (AAIC) 2024 reveal that this dual-acting antibody is not... |
| 30.07.2024 | Long-term lecanemab data show increased patient benefit with maintained safety profile | Long-term lecanemab data show increased patient benefit with maintained safety profile
Tue, Jul 30, 2024 23:00 CET Report this content
Stockholm, Sweden July 30, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today pr... |
| 27.07.2024 | Lecanemab's EU Setback: A Race Against Time for Alzheimer's Treatment | In a world where time is a precious commodity, the recent decision by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has sent ripples of disappointment through the Alzheimer’s community. On ... |
| 27.07.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | The Alzheimer’s Association International Conference (AAIC) 2024 is set to unveil groundbreaking data on lecanemab, a drug that could reshape the landscape of Alzheimer’s disease (AD) treatment. As the conference approaches, excitement is p... |
| 26.07.2024 | CHMP has adopted a negative opinion on lecanemab for the EU | CHMP has adopted a negative opinion on lecanemab for the EU
Fri, Jul 26, 2024 12:40 CET Report this content
Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) h... |
| 26.07.2024 | Eisai will seek re-examination of CHMP opinion för lecanemab | Eisai will seek re-examination of CHMP opinion för lecanemab
Fri, Jul 26, 2024 13:15 CET Report this content
Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will req... |
| 23.07.2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024
Tue, Jul 23, 2024 08:00 CET Report this content
Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will presen... |
| 22.07.2024 | EISAI TO PRESENT DUAL-ACTING LECANEMAB THREE YEAR EFFICACY AND SAFETY DATA AND DISCUSS LONG-TERM OUTCOMES OF CONTINUED TREATMENT AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2024 | Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline will be shared, including the importance of continued treatment of AD, which is a progressive neurodegenerative disease that begins before plaque deposition and continues... |
| 12.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Israel | Leqembi approved for the treatment of Alzheimer’s disease in Israel
Fri, Jul 12, 2024 01:30 CET Report this content
Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqem... |
| 11.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong
Thu, Jul 11, 2024 01:30 CET Report this content
Stockholm, Sweden, July 11, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that th... |
| 28.06.2024 | Leqembi[®] (lecanemab) launched in China | Leqembi[®] (lecanemab) launched in China
Fri, Jun 28, 2024 01:30 CET Report this content
Stockholm, Sweden, June 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (brand name in Ch... |
| 10.06.2024 | FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease | FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease
Mon, Jun 10, 2024 01:30 CET Report this content
Stockholm, Sweden, June 10, 2024 – BioArctic AB’s (publ) (Nasdaq... |
| 24.05.2024 | Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea | Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea
Fri, May 24, 2024 12:55 CET Report this content
Stockholm, Sweden, May 24, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the Ministry o... |
| 17.05.2024 | Interim Report for the period January – March 2024 | Interim Report for the period January – March 2024
Fri, May 17, 2024 08:00 CET Report this content
First BrainTransporter technology agreement signed
Events during the first quarter 2024 Leqembi® was approved for the treatment of Alzheimer'... |
| 15.05.2024 | Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing | Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
Wed, May 15, 2024 01:30 CET Report this content
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasda... |
| 15.05.2024 | Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025) | Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)
Wed, May 15, 2024 05:45 CET Report this content
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) part... |
| 14.05.2024 | Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track St... | TOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbac... |
| 07.05.2024 | Invitation to presentation of BioArctic’s first quarter report for January - March 2024 on May 17 at 9:30 a.m. CET | Invitation to presentation of BioArctic’s first quarter report for January - March 2024 on May 17 at 9:30 a.m. CET
Tue, May 07, 2024 08:30 CET Report this content
Stockholm, Sweden, May 7, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA ... |
| 24.04.2024 | Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024 | Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
Wed, Apr 24, 2024 12:45 CET Report this content
Stockholm, Sweden, April 24, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 20.04.2024 | BioArctic and Eisai sign research evaluation agreement regarding BAN2802 | BioArctic and Eisai sign research evaluation agreement regarding BAN2802
Sat, Apr 20, 2024 09:40 CET Report this content
Stockholm, Sweden, April 20, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB an... |
| 19.04.2024 | Notice of Annual General Meeting in BioArctic AB (publ) | Notice of Annual General Meeting in BioArctic AB (publ)
Fri, Apr 19, 2024 08:00 CET Report this content
The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Wednesday on 22 M... |
| 18.04.2024 | BioArctic publishes the Annual Report for 2023 | BioArctic publishes the Annual Report for 2023
Thu, Apr 18, 2024 08:00 CET Report this content
Stockholm April 18, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for 2023 has been published.
Th... |
| 16.04.2024 | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Tue, Apr 16, 2024 15:00 CET Report this content
Stockholm April 16, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) her... |
| 10.04.2024 | BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm | BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
Wed, Apr 10, 2024 08:00 CET Report this content
Stockholm, Sweden, April 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: ... |
| 01.04.2024 | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed
Mon, Apr 01, 2024 01:40 CET Report this content
Stockholm, Sweden, April 1, 2024 – BioArctic AB’... |
| 22.03.2024 | Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons | Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
Fri, Mar 22, 2024 12:30 CET Report this content
Stockholm, Sweden March 22, 2024 – BioArctic AB:... |
| 19.03.2024 | Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease | Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease
Tue, Mar 19, 2024 08:00 CET Report this content
Stockholm, Sweden, March 19, 2024 – B... |
| 11.03.2024 | New data on lecanemab presented at the 2024 AD/PD™ congress | New data on lecanemab presented at the 2024 AD/PD™ congress
Mon, Mar 11, 2024 08:00 CET Report this content
Stockholm, March 11, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and its partner Eisai presented new data on lecanemab (br... |
| 07.03.2024 | BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference | BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
Thu, Mar 07, 2024 06:30 CET Report this content
Stockholm, Sweden, March 7, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) part... |
| 29.02.2024 | Number of shares and votes in BioArctic AB (publ) as of February 29, 2024 | Number of shares and votes in BioArctic AB (publ) as of February 29, 2024
Thu, Feb 29, 2024 18:30 CET Report this content
Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during ... |
| 29.02.2024 | Latest data on lecanemab to be presented at the 2024 AD/PD™ congress | Latest data on lecanemab to be presented at the 2024 AD/PD™ congress
Thu, Feb 29, 2024 08:00 CET Report this content
Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company and its part... |
| 22.02.2024 | BioArctic's CEO Gunilla Osswald Winner of The Arthur D. Little Nordic Life Science Award | BioArctic's CEO Gunilla Osswald Winner of The Arthur D. Little Nordic Life Science Award
Thu, Feb 22, 2024 08:00 CET Report this content
Stockholm, Sweden, February 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today proudly ann... |
| 14.02.2024 | Interim Report for the period October – December 2023 | Interim Report for the period October – December 2023
Wed, Feb 14, 2024 08:00 CET Report this content
Leqembi launched in Japan and approved in China
Events during the fourth quarter 2023
Leqembi was launched in Japan on December 20 which m... |
| 06.02.2024 | Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023 | Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023
Tue, Feb 06, 2024 04:36 CET Report this content
Stockholm, Sweden, February 6, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their qua... |
| 05.02.2024 | Invitation to presentation of BioArctic’s fourth quarter report for October - December 2023 on February 14 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s fourth quarter report for October - December 2023 on February 14 at 9.30 a.m. CET
Mon, Feb 05, 2024 08:30 CET Report this content
Stockholm, Sweden, February 5, 2024 – BioArctic AB (publ) (Nasdaq St... |
| 11.01.2024 | The European Medicines Agency’s Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab | The European Medicines Agency’s Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab
Thu, Jan 11, 2024 07:00 CET Report this content
Stockholm, Sweden, January 11, 2024 – BioArctic AB’s (publ) (Na... |
| 09.01.2024 | Leqembi® approved for the treatment of Alzheimer’s disease in China | Leqembi® approved for the treatment of Alzheimer’s disease in China
Tue, Jan 09, 2024 09:30 CET Report this content
Stockholm, Sweden, January 9, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leq... |
| 13.12.2023 | LEQEMBI® to be launched in Japan for Alzheimer’s disease on December 20 | LEQEMBI® to be launched in Japan for Alzheimer’s disease on December 20
Wed, Dec 13, 2023 03:05 CET Report this content
Stockholm, Sweden, December 13, 2023 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced th... |
| 28.11.2023 | Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect | Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover the drug, I have met with Alzheimer’s patients and their loved ones who are anxious to know whether they may benefit from this new treatment... |
| 20.11.2023 | Lecanemab winner in two categories at The Scrip Awards 2023 | Lecanemab winner in two categories at The Scrip Awards 2023
Mon, Nov 20, 2023 08:30 CET Report this content
Stockholm, November 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai... |
| 08.11.2023 | Interim Report for the period July – September 2023 | Interim Report for the period July – September 2023
Wed, Nov 08, 2023 08:00 CET Report this content
LEQEMBI launched in the US
Events during the third quarter 2023 In July, the FDA approved LEQEMBI® for the treatment of Alzheimer’s disease ... |
| 07.11.2023 | Update relating to LEQEMBI® from Eisai’s investor presentation of their quarterly report published today | Update relating to LEQEMBI® from Eisai’s investor presentation of their quarterly report published today
Tue, Nov 07, 2023 09:15 CET Report this content
Stockholm, Sweden, November 7, 2023 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) ... |
| 07.11.2023 | LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period | LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period
Tue, Nov 07, 2023 04:40 CET Report this content
Stockholm, Sweden, November 7, 2023 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued thei... |
| 01.11.2023 | Invitation to presentation of BioArctic’s third quarter report for July - September 2023 on November 8 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s third quarter report for July - September 2023 on November 8 at 9.30 a.m. CET
Wed, Nov 01, 2023 08:30 CET Report this content
Stockholm, Sweden, November 1, 2023 – BioArctic AB (publ) (Nasdaq Stockh... |
| 25.10.2023 | New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD | New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD
Wed, Oct 25, 2023 23:25 CET Report this content
Stockholm, October 25, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) p... |
| 24.10.2023 | Lecanemab named one of the world's best inventions in 2023 by TIME | Lecanemab named one of the world's best inventions in 2023 by TIME
Tue, Oct 24, 2023 16:50 CET Report this content
Stockholm, October 24, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai are proud to announce today th... |
| 20.10.2023 | BioArctic presents Nomination Committee | BioArctic presents Nomination Committee
Fri, Oct 20, 2023 08:30 CET Report this content
Stockholm, Sweden, October 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on June 1, 2023, adopted an instruction re... |
| 16.10.2023 | New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD | New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD
Mon, Oct 16, 2023 08:00 CET Report this content
Stockholm, October 16, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIO... |
| 25.09.2023 | “LEQEMBI[®] Intravenous Infusion” approved for the treatment of Alzheimer’s disease in Japan | “LEQEMBI[®] Intravenous Infusion” approved for the treatment of Alzheimer’s disease in Japan
Mon, Sep 25, 2023 07:00 CET Report this content
Stockholm, September 25, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai anno... |
| 23.08.2023 | BioArctic receives patent in Japan for new antibodies targeting Parkinson’s disease | BioArctic receives patent in Japan for new antibodies targeting Parkinson’s disease
Wed, Aug 23, 2023 10:45 CET Report this content
Stockholm, August 23, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanes... |
| 20.07.2023 | Latest analysis of lecanemab’s effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference | Latest analysis of lecanemab’s effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference
Thu, Jul 20, 2023 01:30 CET Report this content
Stockholm, July 20, 2023 – BioArctic AB’s (publ) ... |
| 12.07.2023 | Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC) 2023 | Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC) 2023
Wed, Jul 12, 2023 01:30 CET Report this content
Stockholm, July 12, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eis... |
| 12.07.2023 | Interim Report for the period April – June 2023 | Interim Report for the period April – June 2023
Wed, Jul 12, 2023 08:00 CET Report this content
LEQEMBI® approved in the US – the world’s first fully approved disease-modifying treatment for Alzheimer’s disease
Events during the second quar... |
| 07.07.2023 | FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer’s disease | FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer’s disease
Fri, Jul 07, 2023 02:00 CET Report this content
Stockholm, July 7, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai ... |
| 05.07.2023 | Invitation to presentation of BioArctic’s second quarter report for April - June 2023 on July 12 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s second quarter report for April - June 2023 on July 12 at 9.30 a.m. CET
Wed, Jul 05, 2023 08:30 CET Report this content
Stockholm, Sweden, July 5, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA ... |
| 10.06.2023 | FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer’s disease | FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer’s disease
Sat, Jun 10, 2023 01:00 CET Report this content
Stockholm, June 10, 2023 – BioArctic AB’s (publ... |
| 08.06.2023 | Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease filed in South Korea | Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease filed in South Korea
Thu, Jun 08, 2023 01:30 CET Report this content
Stockholm, June 8, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) par... |
| 01.06.2023 | Report from BioArctic AB’s (publ) Annual General Meeting | Report from BioArctic AB’s (publ) Annual General Meeting
Thu, Jun 01, 2023 19:00 CET Report this content
Stockholm, 1 June 2023. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today, where... |
| 29.05.2023 | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31!
Mon, May 29, 2023 09:45 CET Report this content
It is finally time for BioStock Life Science Spring Summit 2023! Around 30 companies from a wide range of... |
| 22.05.2023 | Marketing Authorisation Application for lecanemab submitted in Great Britain | Marketing Authorisation Application for lecanemab submitted in Great Britain
Mon, May 22, 2023 01:30 CET Report this content
Stockholm, May 22, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they ... |
| 17.05.2023 | Societal value of lecanemab in Japan published in Neurology and Therapy | Societal value of lecanemab in Japan published in Neurology and Therapy
Wed, May 17, 2023 01:30 CET Report this content
Stockholm, May 17, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication... |
| 16.05.2023 | Health Canada accepts New Drug Submission for lecanemab as treatment for early Alzheimer’s disease | Health Canada accepts New Drug Submission for lecanemab as treatment for early Alzheimer’s disease
Tue, May 16, 2023 01:30 CET Report this content
Stockholm, May 16, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai anno... |
| 16.05.2023 | BioArctic repurchases employee stock options from CEO | BioArctic repurchases employee stock options from CEO
Tue, May 16, 2023 18:00 CET Report this content
Stockholm, May 16, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) today announced that the company’s Board of Directors has decid... |
| 16.05.2023 | Correction of press release: BioArctic repurchases employee stock options from CEO | Correction of press release: BioArctic repurchases employee stock options from CEO
Tue, May 16, 2023 20:30 CET Report this content
In the press release the company published at 18.00 CET on May 16, there was an incorrect value of the consid... |
| 03.05.2023 | Notice of Annual General Maating in BioArctic AB (publ) | Notice of Annual General Maating in BioArctic AB (publ)
Wed, May 03, 2023 20:30 CET Report this content
The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, June 1, 2023
More in... |
| 27.04.2023 | Interim Report for the period January – March 2023 | Interim Report for the period January – March 2023
Thu, Apr 27, 2023 08:00 CET Report this content
Applications for market approval of lecanemab submitted on three continents
Events during the first quarter 2023 On January 6, the FDA approv... |
| 27.04.2023 | BioArctic publishes the Annual Report for 2022 | BioArctic publishes the Annual Report for 2022
Thu, Apr 27, 2023 08:00 CET Report this content
Stockholm April 27, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for 2022 has been published.
Th... |
| 19.04.2023 | Invitation to presentation of BioArctic’s first quarter report for January - March 2023 on April 27 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s first quarter report for January - March 2023 on April 27 at 9.30 a.m. CET
Wed, Apr 19, 2023 08:30 CET Report this content
Stockholm, Sweden, April 19, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: ... |
| 04.04.2023 | Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published | Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published
Tue, Apr 04, 2023 01:30 CET Report this content
Stockholm, April 4, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced t... |
| 04.04.2023 | Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published | STOCKHOLM, April 4, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today announced that its partner Eisai has published an article about long-term health outcomes of anti-amyloid-beta (Aβ) protofibril[1] antibody lecane... |
| 03.04.2023 | New lecanemab-data presented at the AD/PD™ 2023 conference | New lecanemab-data presented at the AD/PD™ 2023 conference
Mon, Apr 03, 2023 08:00 CET Report this content
Stockholm, April 3, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanem... |
| 03.04.2023 | BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference | STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid beta (Aβ) protofibril antibody ... |
| 31.03.2023 | Eisai publishes additional detailed analyses from lecanemab phase 2b study | Eisai publishes additional detailed analyses from lecanemab phase 2b study
Fri, Mar 31, 2023 08:00 CET Report this content
Stockholm, March 31, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today the public... |
| 20.03.2023 | Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal | Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal
Mon, Mar 20, 2023 00:30 CET Report this content
Stockholm, March 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BI... |
| 14.03.2023 | U.S. Veterans' Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer's disease | STOCKHOLM, March 14, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing coverage of LEQEMBI™ (lecanemab-irmb) to veterans livin... |
| 13.03.2023 | U.S. Veterans’ Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer’s disease | U.S. Veterans’ Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer’s disease
Mon, Mar 13, 2023 20:30 CET Report this content
Stockholm, March 13, 2023 – BioArctic AB’... |
| 06.03.2023 | FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease and grants Priority Review | FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease and grants Priority Review
Mon, Mar 06, 2023 00:30 CET Report this content
Stockholm, March 6, 2023 – BioArctic AB’s (publ) (Nas... |
| 28.02.2023 | BioArctic hires Anders Martin-Löf as new CFO | BioArctic hires Anders Martin-Löf as new CFO
Tue, Feb 28, 2023 07:15 CET Report this content
Stockholm, February 28, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited Anders Martin-Löf as i... |
| 28.02.2023 | Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration | Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration
Tue, Feb 28, 2023 00:30 CET Report this content
Stockholm, February 28, 2023 – BioArctic AB’s (publ) (Nasdaq Stockh... |
| 06.02.2023 | The Nomination Committee's proposal for the election of Board members and Chairman of the Board in BioArctic AB | The Nomination Committee's proposal for the election of Board members and Chairman of the Board in BioArctic AB
Mon, Feb 06, 2023 08:30 CET Report this content
Stockholm February 6, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) here... |
| 03.02.2023 | Interim Report for the period October – December 2022 | Interim Report for the period October – December 2022
Fri, Feb 03, 2023 08:00 CET Report this content
The US FDA approved Leqembi™ under the accelerated approval pathway for the treatment of Alzheimer's disease
Events during the fourth quar... |
